These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 39004983

  • 1. [Analysis of the efficacy and safety of preoperative programmed death protein-1 inhibitor combined with chemotherapy in immunotherapy-sensitive patients with locally advanced gastric cancer or adenocarcinoma of the esophagogastric junction].
    Li YJ, Yuan P, Zhai JN, Yao YF, Tan LX, Li ZW, Zhang XY, Wu AW.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Jul 25; 27(7):684-693. PubMed ID: 39004983
    [Abstract] [Full Text] [Related]

  • 2. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
    Xie BW, Zang L, Ma JJ, Sun J, Yang X, Wang ML, Lu AG, Hu WG, Zheng MH.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb 25; 24(2):138-144. PubMed ID: 33508919
    [Abstract] [Full Text] [Related]

  • 3. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
    Li YJ, Zhang L, Dong QS, Cai Y, Zhang YZ, Wang L, Yao YF, Zhang XY, Li ZW, Li YH, Sun YS, Wang WH, Wu AW.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov 25; 24(11):998-1007. PubMed ID: 34823301
    [Abstract] [Full Text] [Related]

  • 4. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
    Tian Y, Wang Q, Wang J, Qiao XY, Zhang J, Lin YC, Li Y, Fan LQ, Yang PG, Zhao Q.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb 25; 24(2):128-137. PubMed ID: 33508918
    [Abstract] [Full Text] [Related]

  • 5. [Safety and efficacy of laparoscopic surgery in locally advanced gastric cancer patients with neoadjuvant chemotherapy combined with immunotherapy].
    Lv JB, Yin YP, Zhang P, Cai M, Chen JH, Li W, Li G, Wang Z, Wang GB, Tao KX.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Jan 25; 26(1):84-92. PubMed ID: 36650004
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and Safety of Neoadjuvant Monoimmunotherapy With PD-1 Inhibitor for dMMR/MSI⁃H Locally Advanced Colorectal Cancer: A Single-Center Real-World Study.
    Zhang X, Yang R, Wu T, Cai X, Li G, Yu K, Li Y, Ding R, Dong C, Li J, Hu R, Feng Q, Li Y.
    Front Immunol; 2022 Jan 25; 13():913483. PubMed ID: 35958603
    [Abstract] [Full Text] [Related]

  • 7. [Multicenter real-world study on safety and efficacy of neoadjuvant therapy in combination with immunotherapy for colorectal cancer].
    Liu XZ, Xiong Z, Xiao BY, Yu GY, Li YJ, Yao YF, Tao KX, Ding PR, Zhang W, Wu AW.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Mar 25; 25(3):219-227. PubMed ID: 35340171
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of neoadjuvant sintilimab in combination with FLOT chemotherapy in patients with HER2-negative locally advanced gastric or gastroesophageal junction adenocarcinoma: an investigator-initiated, single-arm, open-label, phase II study.
    Li N, Li Z, Fu Q, Zhang B, Zhang J, Wan XB, Lu CM, Wang JB, Deng WY, Ma YJ, Bie LY, Wang MY, Li J, Xia QX, Wei C, Luo SX.
    Int J Surg; 2024 Apr 01; 110(4):2071-2084. PubMed ID: 38320099
    [Abstract] [Full Text] [Related]

  • 9. Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4).
    Boku N, Ryu MH, Kato K, Chung HC, Minashi K, Lee KW, Cho H, Kang WK, Komatsu Y, Tsuda M, Yamaguchi K, Hara H, Fumita S, Azuma M, Chen LT, Kang YK.
    Ann Oncol; 2019 Feb 01; 30(2):250-258. PubMed ID: 30566590
    [Abstract] [Full Text] [Related]

  • 10. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial.
    Zhang X, Liang H, Li Z, Xue Y, Wang Y, Zhou Z, Yu J, Bu Z, Chen L, Du Y, Wang X, Wu A, Li G, Su X, Xiao G, Cui M, Wu D, Chen L, Wu X, Zhou Y, Zhang L, Dang C, He Y, Zhang Z, Sun Y, Li Y, Chen H, Bai Y, Qi C, Yu P, Zhu G, Suo J, Jia B, Li L, Huang C, Li F, Ye Y, Xu H, Wang X, Yuan Y, E JY, Ying X, Yao C, Shen L, Ji J, RESOLVE study group.
    Lancet Oncol; 2021 Aug 01; 22(8):1081-1092. PubMed ID: 34252374
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study.
    Jiang H, Yu X, Li N, Kong M, Ma Z, Zhou D, Wang W, Wang H, Wang H, He K, Li Z, Lu Y, Zhang J, Zhao K, Zhang Y, Xu N, Li Z, Liu Y, Wang Y, Wang Y, Teng L.
    J Immunother Cancer; 2022 Mar 01; 10(3):. PubMed ID: 35296556
    [Abstract] [Full Text] [Related]

  • 12. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
    Bao YD, Zhang H, Dong L, Jiang KW, Ye YJ, Wang S, Zhou J.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb 25; 24(2):145-152. PubMed ID: 33508920
    [Abstract] [Full Text] [Related]

  • 13. [Short-term efficacy and safety of the synchronous neoadjuvant chemoradiotherapy with paclitaxel plus carboplatin in stage III adenocarcinoma of esophagogastric junction].
    Ji Y, Peng T, Wang G, Zhang Y, Cao M, Gao Q, Li S.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep 25; 21(9):1019-1024. PubMed ID: 30269322
    [Abstract] [Full Text] [Related]

  • 14. [Enhancing survival outcomes in stage Ⅲ gastric/esophagogastric junction cancer: a retrospective study of immune checkpoint inhibitors and adjuvant chemotherapy based on real-world data].
    Yang XQ, Rao Z, Wei HK, Xue ZC, Liu HY, Duan QF, Sun XW, Wang W.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Apr 25; 27(4):395-402. PubMed ID: 38644245
    [Abstract] [Full Text] [Related]

  • 15. Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study.
    André T, Tougeron D, Piessen G, de la Fouchardière C, Louvet C, Adenis A, Jary M, Tournigand C, Aparicio T, Desrame J, Lièvre A, Garcia-Larnicol ML, Pudlarz T, Cohen R, Memmi S, Vernerey D, Henriques J, Lefevre JH, Svrcek M.
    J Clin Oncol; 2023 Jan 10; 41(2):255-265. PubMed ID: 35969830
    [Abstract] [Full Text] [Related]

  • 16. Trastuzumab in combination with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group.
    Hofheinz RD, Hegewisch-Becker S, Kunzmann V, Thuss-Patience P, Fuchs M, Homann N, Graeven U, Schulte N, Merx K, Pohl M, Held S, Keller R, Tannapfel A, Al-Batran SE.
    Int J Cancer; 2021 Sep 15; 149(6):1322-1331. PubMed ID: 34019698
    [Abstract] [Full Text] [Related]

  • 17. Phase II study of S-1 and oxaliplatin as neoadjuvant chemotherapy for locally advanced adenocarcinoma of the gastric or esophagogastric junction: KSCC1601.
    Iwatsuki M, Orita H, Kobayashi K, Hidaka S, Arigami T, Kusumoto T, Satake H, Oki E, Tsutsumi S, Tobimatsu K, Shimokawa M, Saeki H, Makiyama A, Baba H, Mori M.
    Gastric Cancer; 2022 Jan 15; 25(1):180-187. PubMed ID: 34379229
    [Abstract] [Full Text] [Related]

  • 18. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
    Ouyang GL, Meng WJ, Shu P, Deng XB, Wu B, Jiang D, Zhuang H, Shen YL, Zhou ZG, Wang ZQ, Wang X.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr 25; 22(4):349-356. PubMed ID: 31054549
    [Abstract] [Full Text] [Related]

  • 19. Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial.
    Jiang H, Zheng Y, Qian J, Mao C, Xu X, Li N, Xiao C, Wang H, Teng L, Zhou H, Wang S, Zhu D, Peng B, Shen L, Xu N.
    BMC Cancer; 2020 Aug 14; 20(1):760. PubMed ID: 32795349
    [Abstract] [Full Text] [Related]

  • 20. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
    Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, Liu T, Schenker M, Yanez P, Tehfe M, Kowalyszyn R, Karamouzis MV, Bruges R, Zander T, Pazo-Cid R, Hitre E, Feeney K, Cleary JM, Poulart V, Cullen D, Lei M, Xiao H, Kondo K, Li M, Ajani JA.
    Lancet; 2021 Jul 03; 398(10294):27-40. PubMed ID: 34102137
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.